Trial Information

Summary: Phase II - Assessing the efficacy and safety of a new investigational drug when used together with a stable dose of L-dopa in the treatment of Parkinson's Disease

The purpose of the study is to assess the efficacy and safety of a range of doses of a new investigational drug when used together with a stable dose of L-dopa to treat Parkinson's Disease.

Patient Inclusion Criteria:

• Moderate to severe Parkinson's Disease for at least five years, experiencing motor fluctuation and dyskinesias
• Age 30 and older
• Must have been on L-dopa for at least two years, dose must have been stable for the past four months
• Hoehn and Yahr score: 2.5 - 4 in the "off" states

Patient Exclusion Criteria:

• History or presence of major psychological disorders
• Unstable medical conditions
• Consumption of more than 8oz of alcohol per day
• Taking the drugs tolcapone or hepatotoxic drugs

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:33:41 AM